|
CA2694406C
(en)
*
|
2007-07-26 |
2019-03-26 |
Amsterdam Molecular Therapeutics (Amt) B.V. |
Baculoviral vectors comprising repeated coding sequences with differential codon biases
|
|
GB0911870D0
(en)
|
2009-07-08 |
2009-08-19 |
Ucl Business Plc |
Optimised coding sequence and promoter
|
|
EP2545165B1
(en)
*
|
2010-03-11 |
2020-07-29 |
uniQure IP B.V. |
Mutated rep encoding sequences for use in aav production
|
|
WO2011122950A1
(en)
|
2010-04-01 |
2011-10-06 |
Amsterdam Molecular Therapeutics (Amt) Ip B.V. |
Monomeric duplex aav vectors
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
US20140155469A1
(en)
|
2011-04-19 |
2014-06-05 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors and viruses
|
|
GB201210357D0
(en)
|
2012-06-12 |
2012-07-25 |
Ucl Business Plc |
Factor VIII sequences
|
|
WO2015060722A1
(en)
|
2013-10-24 |
2015-04-30 |
Uniqure Ip B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
|
PL3117005T3
(pl)
|
2014-03-10 |
2024-11-04 |
Uniqure Ip B.V. |
Dodatkowo ulepszone wektory aav produkowane w komórkach owadzich
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016073693A2
(en)
|
2014-11-05 |
2016-05-12 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
CA2975583A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
US11021762B2
(en)
|
2014-11-28 |
2021-06-01 |
Uniqure Ip B.V. |
DNA impurities in a composition comprising a parvoviral virion
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
LT3237618T
(lt)
|
2014-12-24 |
2019-07-10 |
Uniqure Ip B.V. |
Rnri sukeltas hantingtino geno slopinimas
|
|
NZ744418A
(en)
*
|
2016-04-21 |
2025-10-31 |
Virovek Inc |
Aav production in insect cells, methods and compositions therefor
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
IL262784B2
(en)
|
2016-05-18 |
2023-10-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
|
EP3491008A2
(en)
|
2016-07-26 |
2019-06-05 |
BioMarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
WO2018109207A1
(en)
|
2016-12-16 |
2018-06-21 |
Uniqure Ip B.V. |
Immunoadsorption
|
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
PT3652326T
(pt)
|
2017-07-10 |
2024-12-26 |
Uniqure Ip Bv |
Meios e métodos para terapia génica de aav em humanos
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
AU2018311069A1
(en)
|
2017-08-03 |
2020-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
CA3084452A1
(en)
|
2017-12-29 |
2019-07-04 |
Uniqure Ip B.V. |
Modified viral vectors and methods of making and using the same
|
|
BR112020014625A2
(pt)
|
2018-01-17 |
2020-12-08 |
Meiragtx Uk Ii Limited |
Proteína de capsídeo de raav modificada para terapia gênica
|
|
GB201800903D0
(en)
|
2018-01-19 |
2018-03-07 |
Oxford Genetics Ltd |
Vectors
|
|
EP3794126A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
JP7565218B2
(ja)
|
2018-07-02 |
2024-10-10 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症および脊髄に関連する障害の治療
|
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
|
GB201813528D0
(en)
|
2018-08-20 |
2018-10-03 |
Ucl Business Plc |
Factor IX encoding nucleotides
|
|
WO2020053258A1
(en)
|
2018-09-12 |
2020-03-19 |
Uniqure Ip B.V. |
Rnai induced c9orf72 suppression for the treatment of als/ftd
|
|
WO2020061418A1
(en)
*
|
2018-09-20 |
2020-03-26 |
Tallgrass Biologics L.L.C. |
Treatment and control of colony collapse disorder
|
|
CN109295172A
(zh)
*
|
2018-09-26 |
2019-02-01 |
浙江海洋大学 |
大黄鱼清道夫受体家族基因的密码子偏好性分析方法
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
CN113166731A
(zh)
|
2018-10-05 |
2021-07-23 |
沃雅戈治疗公司 |
编码aav生产蛋白的工程化核酸构建体
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3867389A1
(en)
|
2018-10-15 |
2021-08-25 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
WO2020104480A1
(en)
|
2018-11-19 |
2020-05-28 |
Uniqure Biopharma B.V. |
Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
|
|
EP3884050A1
(en)
|
2018-11-19 |
2021-09-29 |
uniQure IP B.V. |
Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
|
|
CA3120177A1
(en)
|
2018-11-19 |
2020-05-28 |
Uniqure Ip B.V. |
Method and means to deliver mirna to target cells
|
|
CA3119721A1
(en)
|
2018-11-19 |
2020-05-28 |
Uniqure Ip B.V. |
A companion diagnostic to monitor the effects of gene therapy
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
RS66255B1
(sr)
|
2019-07-15 |
2024-12-31 |
Meiragtx Uk Ii Ltd |
Modifikovani proteini aav kapsida za lečenje artritične bolesti
|
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
WO2021041375A1
(en)
*
|
2019-08-26 |
2021-03-04 |
Rootpath Genomics, Inc. |
Compositions and methods for producing adeno-associated viral vectors
|
|
TW202122582A
(zh)
|
2019-08-26 |
2021-06-16 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
|
EP4031148A1
(en)
|
2019-09-16 |
2022-07-27 |
uniQure IP B.V. |
Targeting misspliced transcripts in genetic disorders
|
|
KR20220110781A
(ko)
*
|
2019-12-04 |
2022-08-09 |
상가모 테라퓨틱스, 인코포레이티드 |
재조합 aav를 생산하기 위한 신규 조성물 및 방법
|
|
WO2021168362A1
(en)
|
2020-02-21 |
2021-08-26 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
WO2021195491A2
(en)
*
|
2020-03-26 |
2021-09-30 |
Asklepios Biopharmaceutical, Inc. |
Inducible promoter for viral vector production
|
|
EP4127146A1
(en)
*
|
2020-04-02 |
2023-02-08 |
uniQure biopharma B.V. |
Novel cell line
|
|
AU2021250656A1
(en)
|
2020-04-02 |
2022-09-15 |
Uniqure Biopharma B.V. |
Dual bifunctional vectors for AAV production
|
|
EP4133074A1
(en)
|
2020-04-07 |
2023-02-15 |
uniQure IP B.V. |
Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
|
|
KR20230020394A
(ko)
|
2020-04-15 |
2023-02-10 |
보이저 테라퓨틱스, 인크. |
Tau 결합 화합물
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
AU2021315876A1
(en)
|
2020-07-27 |
2023-02-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4301768A2
(en)
|
2021-03-03 |
2024-01-10 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022188797A1
(en)
|
2021-03-09 |
2022-09-15 |
Huigene Therapeutics Co., Ltd. |
Engineered crispr/cas13 system and uses thereof
|
|
WO2022214635A1
(en)
|
2021-04-08 |
2022-10-13 |
Stichting Vu |
Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
|
|
US20240374755A1
(en)
|
2021-06-02 |
2024-11-14 |
Uniqure Biopharma B.V. |
Adeno-associated virus vectors modified to bind High-Density Lipoprotein
|
|
WO2022253955A2
(en)
|
2021-06-02 |
2022-12-08 |
Uniqure Biopharma B.V. |
Insect cell production of parvoviral vectors with modified capsid proteins
|
|
EP4359525A1
(en)
|
2021-06-21 |
2024-05-01 |
uniQure biopharma B.V. |
Gene constructs for silencing alpha-synuclein and uses thereof
|
|
US20240287545A1
(en)
|
2021-06-21 |
2024-08-29 |
Uniqure Biopharma B.V. |
Improved lysis procedures
|
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
|
EP4377466A4
(en)
*
|
2021-07-28 |
2025-11-05 |
Biomarin Pharm Inc |
LARGE-SCALE ADENE-ASSOCIATED VIRUS PRODUCTION SYSTEMS
|
|
EP4392434A1
(en)
|
2021-08-26 |
2024-07-03 |
uniQure biopharma B.V. |
Insect cell-produced high potency aav vectors with cns-tropism
|
|
EP4433490A2
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CN114703203B
(zh)
*
|
2022-02-11 |
2024-08-06 |
上海渤因生物科技有限公司 |
杆状病毒载体及其用途
|
|
EP4508216A1
(en)
|
2022-04-12 |
2025-02-19 |
uniQure biopharma B.V. |
Nucleic acid regulation of snca
|
|
WO2023198702A1
(en)
|
2022-04-12 |
2023-10-19 |
Uniqure Biopharma B.V. |
Nucleic acid regulation of c9orf72
|
|
WO2023198662A1
(en)
|
2022-04-12 |
2023-10-19 |
Uniqure Biopharma B.V. |
Novel systems for nucleic acid regulation
|
|
EP4508213A1
(en)
|
2022-04-12 |
2025-02-19 |
uniQure biopharma B.V. |
Nucleic acid regulation of apoe
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4644556A1
(en)
|
2022-12-28 |
2025-11-05 |
FUJIFILM Corporation |
Method for producing adeno-associated virus, and vector set
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218190A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Generation of adeno-associated virus capsid libraries for insect cells
|
|
WO2024218204A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Gene delivery vehicles comprising rna and antibodies
|
|
WO2024218192A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2024261220A1
(en)
|
2023-06-23 |
2024-12-26 |
Uniqure Biopharma B.V. |
Novel fragile x constructs
|
|
TW202525832A
(zh)
|
2023-08-31 |
2025-07-01 |
美商戴諾治療公司 |
衣殼多肽及其使用方法(二)
|
|
WO2025051805A1
(en)
|
2023-09-04 |
2025-03-13 |
Uniqure Biopharma B.V. |
Novel neurotropic recombinant adeno-associated virus particles
|
|
WO2025078602A1
(en)
|
2023-10-11 |
2025-04-17 |
Uniqure Biopharma B.V. |
Nucleic acid regulation of msh3 in repeat expansion disorders
|
|
WO2025078606A1
(en)
|
2023-10-11 |
2025-04-17 |
Uniqure Biopharma B.V. |
Further novel systems for nucleic acid regulation
|
|
WO2025078598A1
(en)
|
2023-10-11 |
2025-04-17 |
Uniqure Biopharma B.V. |
Novel nucleic acid regulation of huntingtin gene
|
|
WO2025114524A1
(en)
|
2023-11-30 |
2025-06-05 |
Uniqure Biopharma B.V. |
Formulations for viral drug products
|
|
WO2025171227A1
(en)
|
2024-02-08 |
2025-08-14 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2025219443A1
(en)
|
2024-04-19 |
2025-10-23 |
Uniqure Biopharma B.V. |
Nucleic acid for a1at regulation
|